The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 346 participants.
Also called NCT01664247
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 346 participants
- Sponsor
- Registry
-
NCT01664247 -
2011-004665-32
-
- Main results
- Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, France, Germany, Israel, Italy, Serbia, South Africa, Ukraine, United Arab Emirates, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01664247. Randomized; double masking; primary purpose treatment. Start 2012-10-01 (actual); primary completion 2013-12-31 (actual). Results posted on 2016-04-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- placebo
- Intervention (Drug)
- liraglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01664247- Content hash
ece750d0119add4467e64c364fd16500ad1be259332326771950adbabe230e5a